Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3-Reference-Cited by-同舟云学术

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

Published:2020-12-21 Issue:1 Volume:5 Page:e510
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Eskelund Christian Winther,Dimopoulos Kostas,Kolstad Arne,Glimelius Ingrid,Räty Riikka,Gjerdrum Lise Mette Rahbek,Sonnevi Kristina,Josefsson Pär,Nilsson-Ehle Herman,Bentzen Hans H. N.,Fagerli Unn Merete,Kuittinen Outi,Haaber Jacob,Niemann Carsten Utoft,Pedersen Lone Bredo,Larsen Maria Torp,Geisler Christian Hartmann,Hutchings Martin,Jerkeman Mats,Grønbæk Kirsten

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference19 articles.

1. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.;Geisler;Blood,2008

2. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.;Hermine;Lancet,2016

3. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.;Romaguera;J Clin Oncol,2005

4. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma.;Le Gouill;N Engl J Med,2017

5. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.;Kolstad;Blood,2014

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study;Blood;2024-08-29

2. CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression;Blood Advances;2024-08-16

3. Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies;2024-05-02

4. The prognostic significance of POD24 in peripheral T-cell lymphoma;Hematology;2024-01-22

5. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial;Blood Advances;2024-01-12